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Background
Late gadolinium enhancement (LGE) with CMR is
commonly assumed to represent myocardial fibrosis;
however, comparative human histological data are lim-
ited, and there is no consensus on the most accurate
method for LGE quantitation. We evaluated the rela-
tionship between CMR assessment of regional fibrosis
and infarct size assessment using serial biomarkers
after ST segment elevation myocardial infarction
(STEMI).
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Figure 1 Correlation between infarct size assessment using biomarkers and CMR-LGE.
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Methods
Ninety-five patients treated for STEMI (59 ± 10 years,
85% male) underwent CMR six months after infarction.
Fibrosis was quantified by CMR-LGE using visual and
automated thresholds, and compared with the rise in
serum biomarkers.
Results
Quantification methods had a strong influence on the
infarct size assessment with CMR-LGE. Significant cor-
relations were observed between LGE and biomarkers
across a range of signal intensity thresholds (range: 2-10
standard deviations [SD] above reference myocardium),
however there was a wide range with respect to estima-
tion of total LGE size (from 6.8 ± 7.7 to 32.1 ± 11.3
grams) and a smaller variation in the correlation with
peak troponin level (R-values ranging from 0.715 to
0.834). The strongest correlation was observed at
thresholds of 5 and 6 SD (R = 0.830, P < 0.001 and R =
0.834, P < 0.001).
Conclusions
There is a wide variation for the correlation between
CMR-LGE quantification of infarct size and biomarker
release following STEMI at a range of automated
thresholds, with the strongest correlations at 5SD and
6SD thresholds.
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